Last edition
News about "AbbVie"
AbbVie Provides US Regulatory Update on TrenibotE BLA
AbbVie gets US FDA Complete Response Letter (CRL) for TrenibotE BLA tied to manufacturing processes; no new clinical studies needed.
AbbVie | 24/04/2026 | By News Bureau
Haisco Signs Exclusive Deal with AbbVie to Develop Novel Pain Therapies
Haisco partners with AbbVie to develop novel pain therapies, with multiple compounds in preclinical to Phase 1 stages targeting pain-related conditions.
AbbVie | 13/04/2026 | By News Bureau | 122
AbbVie reported positive Phase III results showing epcoritamab improved progression-free survival versus standard chemoimmunotherapy in relapsed/refractory diffuse large B-cell lymphoma, reinforcing its potential as a CD3xCD20 bispecific therapy.
AbbVie | 19/01/2026 | By News Bureau | 178
AbbVie Aligns Drug Development and Manufacturing Plans for Obesity Portfolio
AbbVie is moving to establish a strong presence in the obesity treatment market, with a strategy that emphasizes manufacturing scalability, supply readiness, and long-term production efficiency alongside clinical development.
AbbVie | 16/01/2026 | By Darshana | 142
AbbVie and RemeGen, a China-based innovative biopharmaceutical company, have entered into an exclusive licensing agreement covering the development, manufacturing, and commercialization of RC148, a novel investigational PD-1/VEGF-targeted bispecific antibody for the treatment of advanced solid tumours.
AbbVie | 13/01/2026 | By Darshana | 146
West Pharmaceutical Services has entered a definitive agreement to divest the manufacturing and supply rights of its SmartDose 3.5mL On-Body Delivery System to AbbVie, as part of a strategic portfolio review, with the transaction expected to close in mid-2026.
AbbVie | 13/01/2026 | By News Bureau | 260
Takeda Becomes a BaseLaunch Partner
BaseLaunch has added Takeda as a new pharmaceutical partner to its biotech venture incubator, expanding its network of global pharma backers supporting and funding early-stage drug development startups.
AbbVie | 19/12/2025 | By News Bureau | 116
AbbVie Receives FDA Approval for EPKINLY Combo in Relapsed/Refractory Follicular Lymphoma
AbbVie has secured FDA approval for EPKINLY in combination with rituximab and lenalidomide (EPKINLY + R2), marking the first bispecific antibody combo therapy available for patients with relapsed or refractory follicular lymphoma after at least one prior systemic treatment.
AbbVie | 19/11/2025 | By Dineshwori | 155
Indian Pharmaceutical Alliance Welcomes New Leadership
Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, and Vice President, Indian Pharmaceutical Alliance (IPA), has been appointed President of the alliance, while Glenn Saldanha, Chairman and Managing Director, Glenmark, will serve as the new Vice President.
AbbVie | 04/10/2025 | By Dineshwori | 198
AbbVie has begun a USD 70 million expansion of its AbbVie Bioresearch Center (ABC) in Worcester, Massachusetts, and broken ground on a new North Chicago Active Pharmaceutical Ingredient (API) manufacturing facility.
AbbVie | 01/10/2025 | By Dineshwori | 274
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy